EcoDrugPlus

Proteasome 20s Subunit Alpha 5

Ensembl ID : ENSCHOG00000001002
Gene Symbol: PSMA5
1 Cross references
211 Possible Orthologues:

Proteasome 20s Subunit Alpha 6

Ensembl ID : ENSCHOG00000002847
Gene Symbol: PSMA6
1 Cross references
299 Possible Orthologues:

Proteasome 20s Subunit Alpha 8

Ensembl ID : ENSCHOG00000004801
Gene Symbol: PSMA8
1 Cross references
198 Possible Orthologues:

Proteasome 20s Subunit Beta 1

Ensembl ID : ENSCHOG00000007358
Gene Symbol: PSMB1
1 Cross references
217 Possible Orthologues:

Proteasome 20s Subunit Beta 10

Ensembl ID : ENSCHOG00000003674
Gene Symbol: PSMB10
1 Cross references
172 Possible Orthologues:

Proteasome 20s Subunit Beta 2

Ensembl ID : ENSCHOG00000006149
Gene Symbol: PSMB2
1 Cross references
221 Possible Orthologues:

Proteasome 20s Subunit Beta 4

Ensembl ID : ENSCHOG00000007293
Gene Symbol: PSMB4
1 Cross references
214 Possible Orthologues:

Proteasome 20s Subunit Beta 5

Ensembl ID : ENSCHOG00000007168
Gene Symbol: PSMB5
1 Cross references
220 Possible Orthologues:

Proteasome 20s Subunit Beta 7

Ensembl ID : ENSCHOG00000011328
Gene Symbol: PSMB7
1 Cross references
218 Possible Orthologues:

Proteasome 20s Subunit Beta 8

Ensembl ID : ENSCHOG00000007645
Gene Symbol: PSMB8
1 Cross references
221 Possible Orthologues:

Proteasome 20s Subunit Beta 9

Ensembl ID : ENSCHOG00000007681
Gene Symbol: PSMB9
1 Cross references
214 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 2

Ensembl ID : ENSCHOG00000002720
Gene Symbol: PSMD2
1 Cross references
224 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).